On July 7, 2009, Allos Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing the completion of patient enrollment in the Company's randomized Phase 2b clinical trial comparing pralatrexate to erlotinib (TarcevaŽ) in patients with Stage IIIB/IV non-small cell lung cancer who are, or have been, cigarette smokers who have failed treatment with at least one prior platinum-based chemotherapy regimen. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

(d) Exhibits

99.1   Press Release, dated July 7, 2009, entitled "Allos Therapeutics Completes
       Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with
       Advanced Non-Small Cell Lung Cancer."